Online inquiry

IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6612MR)

This product GTTS-WQ6612MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6612MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ77MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ219MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 13C5.5
GTTS-WQ3163MR IVTScrip™ mRNA-Anti-O-antigen, AR-101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AR-101
GTTS-WQ15905MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ3128MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ2511MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ14397MR IVTScrip™ mRNA-Anti-IFNA1, RhuMAB IFNalpha(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RhuMAB IFNalpha
GTTS-WQ11257MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MEDI4736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW